bristol myers - Search News

News

Bristol-Myers Squibb shares snapped 6-session losing streak

Bristol-Myers Squibb shares snapped six-session losing streak

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24. BMY’s shares lost nearly 11.6% in the preceding six sessions. On a year-to-date basis,

SFGate · 2d

Bristol Myers: Q2 Earnings Snapshot

The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share. The biopharmaceutical company posted revenue of $12.27 billion in the period, also surpassing Street forecasts.

TipRanks on MSN · 8h

Bristol-Myers Squibb’s Earnings Call Highlights Growth and Challenges

Bristol-Myers Squibb Company (($BMY)) has held its Q2 earnings call. Read on for the main highlights of the call. Bristol-Myers Squibb’s recent

10h

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its ...

1hon MSN

Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

2don MSN

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

1don MSN

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

3don MSN

Bristol Myers, Bain Capital form new company to develop immunology drugs

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

BioPharma Dive4d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Fierce Pharma1d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

14don MSN

Bristol Myers drug fails main goal in cancer-linked anemia trial

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results